• Kedrion joined forces with BPL in 2022
• This is the first ever approval for a BPL product in China
• The China Albumin market is the world's largest
• Launch commenced in April 2023

As the first ever approval for a BPL product in China, this a major milestone for the company, which can now ship to the country on a regular basis. China is by far the largest human Albumin market in the world of 627 tons vs global demand of 1,368 tons in 2021¹.

"We are delighted to be able to provide this product to patients in China," said Bob Rossilli, Chief Commercial Officer for Kedrion Biopharma. "Obtaining this important license and full distribution agreement in China reflects strongly on our current plan for global expansion while highlighting our corporate mission of providing plasma-derived products worldwide, supporting both healthcare professionals and patients every day."

Zhou Xianfeng, Chairman of Board, Hangzhou Jiansheng Medicine Co. Ltd. said, "We are delighted to have partnered with BPL and Kedrion, which are truly committed to making therapies available in all parts of the world by expanding into important new markets such as China."

Kedrion places a high value on the welfare of those who benefit from its products, as well as the communities and individuals with whom it collaborates, and works on a global scale to broaden access to plasma therapies.